Results 101 to 110 of about 872,419 (247)

John Cunningham Virus seroconversion during natalizumab treatment

ABCS Health Sciences
Introduction: Multiple sclerosis is a progressive disease that is difficult to predict, originating in cases of disability. Natalizumab is a highly effective disease-modifying therapy but is associated with greater John Cunningham virus (JCV ...
Erica Freire de Vasconcelos-Pereira, Vanessa Marcon de Oliveira, Cristiane Munaretto Ferreira, Giovanna Arisa Tano de Paula, Maria Tereza Ferreira, Pedro Rippel Salgado, João Américo Domingos, Massaco Satomi, Fabiany Monteiro da Silva, Camila Yamanaka Akamine, Vanessa Terezinha Gubert   +10 more
doaj   +1 more source

Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study [PDF]

André Aires Fernandes, Ana Lídia Neves, Daniela Ferro, Mafalda Seabra, Teresa Mendonça, Ricardo Soares-dos-Reis, María José Sá, Joana Guimarães, Pedro Abreu   +8 more
openalex   +1 more source

Medicinal Mushrooms: A New Source for Breast Cancer Therapeutics [PDF]

, 2005
R. Petrova, Jamal Mahajna, Cvetomir M. Denchev   +2 more
openalex   +1 more source

Prospect for Covid-19 Investigational Drugs: The Timeline (Prospect for Covid-19 Therapeutics)

, 2022
Augustine S. Samorlu
openalex   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

DNA as therapeutics; an update

, 2009
P Saraswat, RR Soni, Abhishek Bhandari, BP Nagori   +3 more
openalex   +1 more source

Cell density–dependent nuclear‐cytoplasmic shuttling of SETDB1 integrates with Hippo signaling to regulate YAP1‐mediated transcription

FEBS Letters, EarlyView.
At low cell density, SETDB1 and YAP1 accumulate in the nucleus. As cell density increases, the Hippo pathway is gradually activated, and SETDB1 is associated with increased YAP1 phosphorylation. At high cell density, phosphorylated YAP1 is sequestered in the cytoplasm, while SETDB1 becomes polyubiquitinated and degraded by the ubiquitin–proteasome ...
Jaemin Eom, Jaewoong Jang, Jung Sun Park, Yong‐Kook Kang   +3 more
wiley   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Materia Medica and Therapeutics

, 1915
&NA;
openalex   +2 more sources

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source